Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    1(33%)
    Results Posted
    100%(1 trials)
    Terminated
    1(33%)

    Phase Distribution

    Not Applicable
    2
    67%
    Phase 2/3
    1
    33%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 2/3Combined phases
    1(33.3%)
    N/ANon-phased studies
    2(66.7%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(1)
    Completed(1)
    Terminated(1)

    Detailed Status

    Completed1
    Recruiting1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    50.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 2/31 (33.3%)
    N/A2 (66.7%)

    Trials by Status

    completed133%
    recruiting133%
    terminated133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    completednot_applicable

    "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

    NCT05410509
    recruitingphase_2_3

    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

    NCT06844357
    terminatednot_applicable

    LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors

    NCT02649868

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT05410509Not Applicable

    "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

    Completed
    NCT06844357Phase 2/3

    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

    Recruiting
    NCT02649868Not Applicable

    LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors

    Terminated

    All 3 trials loaded

    Drug Details

    Intervention Type
    Procedure
    Total Trials
    3